Guest Editors
Dr. Stella Bouziana
Email: styliani.bouziana@nhs.net
Affiliation: Department of Haematology, Comprehensive Cancer Centre, Rayne Institute, King’s College London, London, United Kingdom
Homepage:
Research Interests: cellular therapies, immunotherapies, CAR T-cell therapies, lymphoproliferative diseases, hematopoietic stem cell transplantation
Summary
Cellular and immune-based strategies have been at the forefront of therapeutic innovation by transforming clinical outcomes in patients with haematological malignancies across a range of disease entities. These therapies have achieved a curative potential, especially in patients with lymphoproliferative diseases who have had limited therapeutic options and a dismal prognosis. Substantial refinements have been undertaken since the first introduction of cellular therapies and immunotherapies to address challenges such as pernicious toxicities, the perplex manufacturing process, and risk of relapse, with next-generation platforms currently in the pipeline in order to enhance efficacy and safety.
This Special Issue, entitled "Innovations in Cellular and Immune Therapeutics for Haematological Malignancies: From Experimental Insight to Clinical Impact," aims to compile the latest advances in exploring next-generation chimeric antigen receptor T-cell therapies, engineered natural killer cells, bispecific antibodies, immune checkpoint modulation, and novel cellular platforms designed to enhance efficacy while mitigating toxicity in haematological malignancies. Emphasis is placed on translational research that informs target selection, resistance mechanisms, tumor microenvironment interactions, and biomarkers predictive of response and safety. Contributions on aspects of clinical implementation, including toxicity management, real-world outcomes, manufacturing challenges, and strategies to expand access globally, will be of special interest.
Ultimately, this Special Issue aims to bridge the dynamic interplay between pre-clinical mechanistic discoveries and clinical translation with a view to moving towards more precise, efficacious, and accessible therapies for patients with haematological cancers.
Keywords
haematological malignancies, cellular therapies, immunotherapies, CAR T-cell therapies
Login
Register
Submit a Paper
Propose a Special lssue